Form 4: Supernus Pharmaceuticals Director Exercises Options and Sells Shares
Form 4
Director Georges Gemayel exercised stock options and sold shares of Supernus Pharmaceuticals on November 7, 2024.
Summary
- On November 7, 2024, Georges Gemayel, a director of Supernus Pharmaceuticals, exercised stock options to acquire 14,213 shares of common stock at a price of $11.46 per share.
- Simultaneously, Gemayel sold 14,213 shares of Supernus common stock at a weighted average price of $36.62, with individual sales ranging from $36.50 to $36.89.
- Following these transactions, Gemayel directly owns 13,315 shares of Supernus common stock and holds options for 10,787 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It's common for directors to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
- The sale of shares by a director could have a minor impact on the stock price, depending on market perception.
Key Dates
| Date | Description |
|---|---|
| 03/23/2016 | Original date of the director stock option |
| 03/23/2025 | Expiration date of the director stock option |
| 11/07/2024 | Date of transaction: Exercise of stock options and sale of shares |
| 11/08/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.